0000898432-20-000826.txt : 20201023
0000898432-20-000826.hdr.sgml : 20201023
20201023143815
ACCESSION NUMBER: 0000898432-20-000826
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201016
FILED AS OF DATE: 20201023
DATE AS OF CHANGE: 20201023
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Alaska Permanent Fund Corp
CENTRAL INDEX KEY: 0001582681
STATE OF INCORPORATION: AK
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39615
FILM NUMBER: 201257328
BUSINESS ADDRESS:
STREET 1: 801 WEST 10TH STREET
STREET 2: SUITE 302
CITY: JUNEAU
STATE: AK
ZIP: 99801
BUSINESS PHONE: 907-796-1500
MAIL ADDRESS:
STREET 1: 801 WEST 10TH STREET
STREET 2: SUITE 302
CITY: JUNEAU
STATE: AK
ZIP: 99801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Codiak BioSciences, Inc.
CENTRAL INDEX KEY: 0001659352
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O ARCH VENTURE PARTNERS
STREET 2: 999 THIRD AVENUE, SUITE 3400
CITY: SEATTLE
STATE: WA
ZIP: 98104
BUSINESS PHONE: 857-400-4222
MAIL ADDRESS:
STREET 1: C/O ARCH VENTURE PARTNERS
STREET 2: 999 THIRD AVENUE, SUITE 3400
CITY: SEATTLE
STATE: WA
ZIP: 98104
FORMER COMPANY:
FORMER CONFORMED NAME: Codiak Biosciences, Inc.
DATE OF NAME CHANGE: 20151125
4
1
form4.xml
X0306
4
2020-10-16
0001659352
Codiak BioSciences, Inc.
CDAK
0001582681
Alaska Permanent Fund Corp
801 WEST 10TH STREET
SUITE 302
JUNEAU
AK
99801
true
Common Stock
2020-10-16
4
C
0
2616093
A
4512895
I
See Footnote
Common Stock
2020-10-16
4
C
0
467076
A
4512895
I
See Footnote
Common Stock
2020-10-16
4
C
0
747321
A
4512895
I
See Footnote
Common Stock
2020-10-16
4
C
0
191721
A
4512895
I
See Footnote
Common Stock
2020-10-16
4
C
0
191721
A
4512895
I
See Footnote
Common Stock
2020-10-16
4
P
0
235000
15
A
4512895
I
See Footnote
Series A redeemable convertible preferred stock
2020-10-16
4
C
0
20450000
0
D
Common Stock
2616093
0
I
See Footnotes
Series B redeemable convertible preferred stock
2020-10-16
4
C
0
3333333
0
D
Common Stock
467076
0
I
See Footnote
Series B redeemable convertible preferred stock
2020-10-16
4
C
0
5333333
0
D
Common Stock
747321
0
I
See Footnotes
Series C redeemable convertible preferred stock
2020-10-16
4
C
0
1320097
0
D
Common Stock
191721
0
I
See Footnote
Series C redeemable convertible preferred stock
2020-10-16
4
C
0
1320097
0
D
Common Stock
191721
0
I
See Footnotes
Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock.
The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P..
The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose.
The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC.
The shares are held by ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII Overage, L.P..
The shares are held by ARCH Venture Fund VIII, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII, L.P..
Each share of Series A Preferred Stock converted automatically into Common Stock on a 1-for-7.8170 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020.
Each share of Series B Preferred Stock converted automatically into Common Stock on a 1-for-7.1366 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
Each share of Series C Preferred Stock converted automatically into Common Stock on a 1-for-6.8855 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the Issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering.
The Reporting Person is the Alaska Permanent Fund Corporation, acting for and on behalf of the funds which the Alaska Permanent Fund Corporation is designated by Alaska Statutes 37.13 to manage and invest.
/s/ Angela Rodell
2020-10-21